| abstract |
The present invention relates to a novel polymorphic crystalline Form α of (S)-Pregabalin, to a process for preparing it, to pharmaceutical compositions containing it, as well as its use. Crystalline Form α of (S)-Pregabalin is characterized by an X-ray powder diffraction pattern comprising peaks at about 9.5, 16.5, 17.8, 19.0, 20.0, 23.3° +/- 0.2° 2θ and a differential scanning calorimetry endothermic maximum peak at about 195°C. |